Dr. Moghanaki joins a prestigious board of lung cancer experts committed to attracting top researchers to the field of lung ...

The Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for adults with limited-stage small cell lung cancer ...

Cancer is a complex condition marked by the uncontrolled growth of cells in the body. When this process begins in the lungs, ...

Apart from breathing issues like breathlessness and pain in the chest, signs and symptoms of lung cancer extend way beyond, ...

ProCure Proton Therapy Center marks its 13th anniversary this March, celebrating a legacy of state-of-the-art technology with a patient-centered approach in cancer care. Since 2012, ProCure has helped ...

At only age 28, the newlywed and busy teacher initially dismissed her symptoms. As her cough and fatigue worsened, she ...

A York County business owner is sharing his story of hope after completing an innovative cancer treatment at WellSpan York Hospital. John Grim has been battling prostate cancer for nearly seven ...

Oncology nurses play essential roles in the emerging field of cardio-oncology, which aims to protect patients’ heart function ...

IMFINZITM (durvalumab) has received approval in the European Union as a monotherapy for treating adults with limited-stage ...

As an expert explained in an interview with CURE, we may be in the midst of a “new era” for small cell lung cancer research.

Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo ...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...